Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Eric L. Simpson(Oregon Health & Science University), Marius Ardeleanu(Regeneron (United States)), Jonathan I. Silverberg(George Washington University), Thomas Bieber(CK-CARE), Emma Guttman‐Yassky(Icahn School of Medicine at Mount Sinai), Michael J. Cork(Royal Hallamshire Hospital), Mette Deleuran(Aarhus University Hospital), Yuhwen Soo(Regeneron (United States)), Margitta Worm(Charité - Universitätsmedizin Berlin), Laurent Eckert(Sanofi (France)), J.‐P. Lacour(Centre Hospitalier Universitaire de Nice), Yoko Kataoka(Osaka Prefectural Medical Center), Yves Poulin(ENT and Allergy), Bolanle Akinlade(Regeneron (United States)), Andreas Wollenberg(University Hospital Augsburg), Neil M.H. Graham(UK Dementia Research Institute), Andrew Blauvelt(Veterans Health Administration), Lisa A. Beck(Newcastle University), Neil Stahl(Arthritis and Rheumatism Associates), George D. Yancopoulos(Regeneron (United States)), Heribert Staudinger(Sanofi (United States)), Gianluca Pirozzi(Sanofi (United States)), Vera Mastey(Regeneron (United States)), Abhijit Gadkari(Regeneron (United States)), Külli Kingo(Tartu University Hospital)
Cited by 2,038
Related Papers
Vascular-specific growth factors and blood vessel formation
|Nature|2000|3.7k
Guidelines for the Diagnosis and Management of Food Allergy in the United States: Summary of the NIAID-Sponsored Expert Panel Report
|Journal of Allergy and Clinical Immunology|2010|2.3k
VEGF-Trap: A VEGF blocker with potent antitumor effects
|Proceedings of the National Academy of Sciences|2002|1.7k
Regulation of the Germinal Center Response by MicroRNA-155
|Science|2007|1.5k